112 search results for: type 2 inflammation

ADVENT On Air | Common Drivers of <b>Type</b> <b>2</b> Inflammatory Diseases

Podcast

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

15 min

Type 2 Inflammation

Profs. Klaus Rabe and Stephan Weidinger discuss shared and unique features of type 2 inflammatory diseases and the benefits of multidisciplinary care

How Does Protective <b>Type</b> <b>2</b> Immunity Become Harmful <b>Type</b> <b>2</b> <b>Inflammation</b>?

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

9 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

EoE Burden and Pathophysiology of <b>Type</b> <b>2</b> <b>Inflammation</b>

videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

3 min

Gastroenterology

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

Itch in AD, PN, and CSU: Contributions of <b>Type</b> <b>2</b> <b>Inflammation</b>

expert video

Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation

13 min

Dermatology

In this video from the ADVENT symposium from Fall Clinical 2023, join Dr. Raj Chovatiya as he explores the contribution of type 2 inflammation to itch in AD, PN, and CSU.

A Common Link: The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in the Clinical Presentation of AD, PN, and CSU

expert video

A Common Link: The Role of Type 2 Inflammation in the Clinical Presentation of AD, PN, and CSU

12 min

Dermatology

In this video from the ADVENT symposium at Fall Clinical 2023, join Dr. James Del Rosso as he explores the role of type 2 inflammation in the clinical presentation of AD, PN, and CSU.

CRSwNP: A Chronic <b>Type</b> <b>2</b> Inflammatory Disease

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

The Cycle of <b>Inflammation</b> in Adult Asthma

interactivity

The Cycle of Inflammation in Adult Asthma

5 min

Pulmonology

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients.

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

4 min

Dermatology

In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region